BioCentury | Aug 17, 2015
Product Development

Structure knows best

Although most of Heptares' compounds are against clinically validated targets, and only one currently boasts first-in-class potential, the structure-based drug design company is building a case for its ability to expand targets into new indications,...
Items per page:
1 - 1 of 1